Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2 mutant non small cell lung cancer

PURPOSE: Evaluating drug responses using primary patient derived cells ex vivo represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in HER2 mutant non-small cell lung cancer (NSCLC) patient xenograft deriv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ivanova, Elena, Kuraguchi, Mari, Xu, Man, Portell, Andrew J., Taus, Luke, Diala, Irmina, Lalani, Alshad S., Choi, Jihyun, Chambers, Emily S., Li, Shuai, Liu, Shengwu, Chen, Ting, Barbie, Thanh U., Oxnard, Geoffrey R., Haworth, Jacob J, Wong, Kwok-Kin, Dahlberg, Suzanne E., Aref, Amir A., Barbie, David A., Bahcall, Magda, Paweletz, Cloud P., Jänne, Pasi A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7967092/
https://ncbi.nlm.nih.gov/pubmed/32034078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1844
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados